Print

Increasing access to better and cheaper medicines and diagnostics for HIV/AIDS

Of the approximately 34 million people living with HIV today, about 95% are in low- and middle-income countries. Over the last decade, smart investments have turned the tide on the HIV/AIDS epidemic in these countries. Millions of lives have been saved thanks to prevention, testing and treatment efforts. In 2011, 8 million of the estimated 14.8 million people eligible for treatment in low- and middle-income countries were receiving HIV/AIDS treatment, according to UNAIDS.

HIV Treatment

UNITAID has played a critical role in building this market by focusing on paediatric medicines, second-line medicines and integrated prevention of mother-to-child transmission of HIV. By intervening in these "niche markets", UNITAID has addressed gaps in global public health funding for HIV/AIDS treatment. Click below for an overview of our work in HIV treatments.

Read more

HIV Diagnostics – Point-of-Care and Decentralized Testing and Monitoring

In 2012, UNITAID today announced the largest yet investment in point-of-care and decentralized HIV diagnostic products. Click below for more information on our work with point-of-care and decentralized HIV diagnostics.

Read more

Discover our individual HIV projects here:

Paediatric HIVAIDS Project  Second-line Adult Antiretroviral Project
 
ESTHERAID Accelerating Access to Innovative Point-of-Care HIV Diagnostics
 
Prevention of Mother-To-Child Transmission of HIV Implementation of CD4 and Viral Load Testing

 
CPP-small

Last updated June 2012

Implementing partners

partners